August 6, 2024

Claire Mazumdar
Chief Executive Officer
Bicara Therapeutics Inc.
116 Huntington Avenue, Suite 703
Boston, MA 02116

        Re: Bicara Therapeutics Inc.
            Amendment No. 1 to Draft Registration Statement on Form S-1
            Submitted July 22, 2024
            CIK No. 0002023658
Dear Claire Mazumdar:

     We have reviewed your amended draft registration statement and have the
following
comments.

        Please respond to this letter by providing the requested information
and either submitting
an amended draft registration statement or publicly filing your registration
statement on EDGAR.
If you do not believe a comment applies to your facts and circumstances or do
not believe an
amendment is appropriate, please tell us why in your response.

        After reviewing the information you provide in response to this letter
and your amended
draft registration statement or filed registration statement, we may have
additional
comments. Unless we note otherwise, any references to prior comments are to
comments in our
July 5, 2024 letter.

Amendment No. 1 to Draft Registration Statement on Form S-1
Prospectus Summary
Ficerafusp alfa clinical results, page 3

1.      We note your response to prior comment 3 and reissue in part. Please
revise where you
        discuss obtaining accelerated approval to include balancing disclosure
that an accelerated
        approval pathway may not lead to a faster development or regulatory
review or approval
        process and does not increase the likelihood that your product
candidate will receive
        marketing approval.
2.      We note your response to prior comment 6 and reissue in part. Please
revise this section to
        disclose, as indicated in your response, that you cannot derive
statistical significance from
        this phase of your clinical trials.
 August 6, 2024
Page 2

Risk Factors
Risks Related to Our Dependence on and Work with Third Parties, page 33

3.     We note your revised disclosure in response to prior comment 21. Please
revise your Risk
       Factors section to disclose the risks relating to the Biocon Agreement's
termination
       provision permitting termination upon reasonable advance notification by
either party,
       how it may disrupt the development of ficerafusp alfa, or otherwise
advise.
Business
Ficerafusp alfa synergizes with anti-PD-1 therapies, with anti-tumor activity
superior to other
anti-EGFR therapies in preclinical models, page 110

4.     We note your response to prior comment 15 and reissue. Please revise to
disclose the
       design, data and results of the two preclinical cancer mouse models
whose data were
       published in Cancer Research. Regarding design, revise to disclose the
number of mice
       receiving each treatment and the number of mice in control groups,
whether the the tests
       were powered for statistical significance and if so, state whether the
results were
       statistically significant. Provide the data relied on for your
conclusion that "the relapse
       rate of tumors in ficerafusp alfa-treated mice were minimal compared
with cetuximab-
       treated mice;" that "treatment with ficerafusp alfa led to an improved
response as
       compared to cetuximab combination;" and that you "believe this data
supports the ability
       of BCA101ficerafusp alfa to prevent TGF-B from inducing resistance to
EGFR-directed
       therapy and TGF-B-driven immunosuppression."
       Please contact Tara Harkins at 202-551-3639 or Vanessa Robertson at
202-551-3649 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Daniel Crawford at 202-551-7767 or Tim Buchmiller at 202-551-3635 with
any other
questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Gabriela Morales-Rivera, Esq.